The Centers for Medicare & Medicaid Services today announced a new Section 1115 waiver policy that allows states to design demonstration projects that increase access to treatment for opioid use disorders and other substance use disorders. CMS’s new demonstration policy would allow state Medicaid programs to reimburse for substance abuse treatment provided at inpatient facilities with more than 16 beds otherwise prohibited by the current Institutions for Mental Diseases exclusion. While the new policy will provide states with an expedited review process, it does require that states submit a detailed implementation plan that articulates how they will meet the new policy’s specific goals and milestones to improve OUD and SUD treatment and reduce opioid related deaths. In addition to the implementation plan, states also must comply with periodic reporting and evaluations. CMS also announced approval of New Jersey and Utah’s 1115 demonstration waivers under the new policy.

Related News Articles

Headline
To encourage drug companies to seek approval for over-the-counter versions of naloxone, an emergency treatment for opioid overdose, the Food and Drug…
Headline
Patients in the most rural counties had an 87 percent greater chance of receiving an opioid prescription from their primary care provider between January 2014…
Headline
Continued rising drug prices, as well as shortages for many critical medications, are disrupting patient care and forcing hospitals to delay infrastructure and…
Headline
U.S. overdose death rates linked to synthetic opioids increased more than 45 percent in 2017, likely driven by illicitly manufactured fentanyl, according to a…
Headline
The Health Resources and Services Administration recently launched a program to provide eligible health care clinicians with student loan repayment assistance…
Insights and Analysis
Also in this weekly roundup of health care news: how mandated access to at-home palliative care has made all the difference for some patients; and a town’s…